ID   Hewga-CCS
AC   CVCL_0J32
DR   Wikidata; Q54883210
RX   PubMed=24946937;
RX   PubMed=28745431;
CC   Population: Japanese.
CC   Doubling time: ~44 hours (PubMed=24946937).
CC   Sequence variation: Gene fusion; HGNC; HGNC:783; ATF1 + HGNC; HGNC:3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF; Note=Type 2: EWSR1 exon 7 fused to ATF1 exon 5 (PubMed=24946937; PubMed=28745431).
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3745; Clear cell sarcoma of soft tissue
DI   ORDO; Orphanet_3394; Soft tissue sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 10
//
RX   PubMed=24946937; DOI=10.1186/1471-2407-14-455; PMCID=PMC4076438;
RA   Outani H., Tanaka T., Wakamatsu T., Imura Y., Hamada K.-i., Araki N.,
RA   Itoh K., Yoshikawa H., Naka N.;
RT   "Establishment of a novel clear cell sarcoma cell line (Hewga-CCS),
RT   and investigation of the antitumor effects of pazopanib on
RT   Hewga-CCS.";
RL   BMC Cancer 14:455.1-455.13(2014).
//
RX   PubMed=28745431; DOI=10.1002/cam4.1130; PMCID=PMC5603837;
RA   Nakai T., Imura Y., Tamiya H., Yamada S., Nakai S., Yasuda N., Kaneko K.,
RA   Outani H., Takenaka S., Hamada K., Myoui A., Araki N., Ueda T., Itoh K.,
RA   Yoshikawa H., Naka N.;
RT   "Trabectedin is a promising antitumor agent potentially inducing
RT   melanocytic differentiation for clear cell sarcoma.";
RL   Cancer Med. 6:2121-2130(2017).
//